Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD ‐1 inhibitor (sintilimab) in small cell lung cancer: A case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD ‐1 inhibitor (sintilimab) in small cell lung cancer: A case report

Published:2021-05-05 Issue:11 Volume:12 Page:1780-1783
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Li Yi‐hui¹,Zhou Yang¹,Liu Yuan‐yuan¹,Zhang Guang‐ju¹,Xiao Lei¹,Li Na¹,Qin Hai‐feng²,Wang Jian‐gong¹^ORCID,Zhang Li³

Affiliation:

1. Department of Multimodality Therapy Oncology Tangshan People's Hospital Tangshan China

2. Department of Pulmonary Neoplasm Internal Medicine Nanyuan District of 302 Hospital of PLA Beijing China

3. Department of Respiratory Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13967

Reference24 articles.

1. Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature

2. Recent updates on Sintilimab in solid tumor immunotherapy

3. Adverse events associated with immune checkpoint inhibitor treatment for cancer

4. Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

5. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine release syndrome triggered by programmed death 1 blockade (sintilimab) therapy in a psoriasis patient: A case report;World Journal of Clinical Cases;2024-06-26

2. Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports;Cancers;2024-05-16

3. Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects;Chinese Medical Journal Pulmonary and Critical Care Medicine;2023-12

4. Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms;Current Drug Targets;2022-12

5. Multi-target combinatory strategy to overcome tumor immune escape;Frontiers of Medicine;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3